JHEP Reports最新文献

{"title":"Copyright and information","authors":"","doi":"10.1016/S2589-5559(25)00088-6","DOIUrl":"10.1016/S2589-5559(25)00088-6","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 4","pages":"Article 101411"},"PeriodicalIF":9.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143761033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Board page","authors":"","doi":"10.1016/S2589-5559(25)00085-0","DOIUrl":"10.1016/S2589-5559(25)00085-0","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 4","pages":"Article 101408"},"PeriodicalIF":9.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143761031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival","authors":"Vincenzo Ronca , Alessandro Parente , Ellina Lytvyak , Bettina E. Hansen , Gideon Hirschfield , Alan Bonder , Maryam Ebadi , Saleh Elwir , Mohamad Alsaed , Piotr Milkiewicz , Maciej K. Janik , Hanns-Ulrich Marschall , Maria Antonella Burza , Cumali Efe , Ali Rıza Calışkan , Murat Harputluoglu , Gökhan Kabaçam , Débora Terrabuio , Fernanda de Quadros Onofrio , Nazia Selzner , Aldo J. Montano-Loza","doi":"10.1016/j.jhepr.2025.101332","DOIUrl":"10.1016/j.jhepr.2025.101332","url":null,"abstract":"<div><h3>Background & Aims</h3><div>A significant proportion of patients with variant syndromes (VSs), namely autoimmune hepatitis/primary biliary cholangitis or autoimmune hepatitis/primary sclerosing cholangitis, require liver transplantation (LT) despite treatment. The frequency of disease recurrence and the effect on graft survival are yet to be clarified. The aim of this international, multicentric, retrospective study is to evaluate the risk factors associated with recurrence and the impact of the disease recurrence after LT on graft and patient survival.</div></div><div><h3>Methods</h3><div>We evaluated 166 patients undergoing LT for VS in 33 centers in North America, South America, Europe, and Asia. Clinical data before and after LT, biochemical data within the first 12 months after LT, and immunosuppression after LT were analyzed to identify patients with a higher risk of recurrence of autoimmune disease based on a histological and radiological diagnosis. Cumulative probabilities of graft and overall survival after LT were calculated using a semi-Markov model.</div></div><div><h3>Results</h3><div>The autoimmune pattern of recurrence resembled the original VS in 19 cases (61%). Recurrence of autoimmune liver disease (<em>r</em>ALD) after LT was observed in 23% and 33% of patients after 5 and 10 years, respectively. Increased alkaline phosphatase (hazard ratio [HR] 1.60, 95% confidence interval [CI] 1.13–2.25, <em>p</em> <0.01) and alanine aminotransferase (HR 1.25, 95% CI 1.01–1.53, <em>p</em> = 0.03) at 12 months after LT and acute rejection (HR 3.58, 95% CI 1.60–7.73, <em>p</em> <0.01) were associated with a higher risk of VS recurrence, whereas the use of predniso(lo)ne was associated with a reduced risk (HR 0.30, 95% CI 0.14–0.64, <em>p</em> <0.01). After adjusting for alanine aminotransferase and alkaline phosphatase at 12 months, the use of predniso(lo)ne was found to be independently and negatively associated with recurrent disease. The <em>r</em>ALD was found to be significantly associated with graft loss and patient survival in the multivariate Cox regression analysis with a time-dependent covariate. The 5- and 10-year probabilities of graft survival were 68% and 41% in patients with recurrent VS compared with 83% and 60% in patients without recurrent disease, respectively (<em>p</em> = 0.01). The overall survival was significantly reduced in patients with recurrent disease (<em>p</em> = 0.01), with event probability at 5 and 10 years of 75% and 49% <em>vs</em>. 84% and 60% in patients without recurrence, respectively.</div></div><div><h3>Conclusions</h3><div><em>r</em>ALD after LT is frequent and is associated with elevation in liver enzymes within the first year after LT and rejection episodes. According to our data, VS recurrence appears to be associated with poorer graft and patient survival. Further studies are needed to explore strategies that can prevent VS recurrence or mitigate its potential impact.</div></d","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 5","pages":"Article 101332"},"PeriodicalIF":9.5,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143815575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: “Trans-splenic anterograde coil assisted transvenous obliteration vs. retrograde transvenous obliteration: Are we heading the right way?”","authors":"Marco Senzolo , Michele Battistel , Stefano Groff , Alberto Zanetto , Giulio Barbiero , Sarah Shalaby","doi":"10.1016/j.jhepr.2025.101389","DOIUrl":"10.1016/j.jhepr.2025.101389","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 5","pages":"Article 101389"},"PeriodicalIF":9.5,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143748547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: “Dynamic imaging of macrophages in MASLD: A major interest in insulin resistance and outside the liver”","authors":"Yongjian Liu , Joel D. Schilling","doi":"10.1016/j.jhepr.2025.101386","DOIUrl":"10.1016/j.jhepr.2025.101386","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 5","pages":"Article 101386"},"PeriodicalIF":9.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum regarding previously published articles","authors":"","doi":"10.1016/j.jhepr.2025.101359","DOIUrl":"10.1016/j.jhepr.2025.101359","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 3","pages":"Article 101359"},"PeriodicalIF":9.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143592489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copyright and information","authors":"","doi":"10.1016/S2589-5559(25)00055-2","DOIUrl":"10.1016/S2589-5559(25)00055-2","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 3","pages":"Article 101378"},"PeriodicalIF":9.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143592490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Board page","authors":"","doi":"10.1016/S2589-5559(25)00052-7","DOIUrl":"10.1016/S2589-5559(25)00052-7","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 3","pages":"Article 101375"},"PeriodicalIF":9.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143592487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel in vitro system for simultaneous infections with hepatitis B, C, D and E viruses","authors":"Roxanne Fouillé ,&nbsp;Eloi R. Verrier ,&nbsp;Amse De Meyer ,&nbsp;Lieven Verhoye ,&nbsp;Maud Michelet ,&nbsp;Romain Barnault ,&nbsp;Caroline Pons ,&nbsp;Olivier Diaz ,&nbsp;Michel Rivoire ,&nbsp;Guillaume Passot ,&nbsp;Eike Steinmann ,&nbsp;Heiner Wedemeyer ,&nbsp;Anna Salvetti ,&nbsp;Nicole Pavio ,&nbsp;Virginie Doceul ,&nbsp;Raphaël Darteil ,&nbsp;Philip Meuleman ,&nbsp;David Durantel ,&nbsp;Julie Lucifora","doi":"10.1016/j.jhepr.2025.101383","DOIUrl":"10.1016/j.jhepr.2025.101383","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>The liver, and more precisely hepatocytes, can be infected by several hepatotropic viruses, including HBV, HDV, HCV and HEV, with chronic infection leading to end-stage liver diseases. Since no <em>in vitro</em> model allowing multi-infections with the four viruses is reported, limited data are available on their interplay as well as on the potential cross-reactivity of antivirals in multi-infection cases. The aim of our study was to set up such a model.</div></div><div><h3>Methods</h3><div>HuH7.5-NTCP cells were cultured with 2% DMSO (dimethyl sulfoxide) for 1 week to allow partial differentiation into hepatocytes (dHuH7.5-NTCP) before infection with the different viruses and treatment with known antiviral molecules.</div></div><div><h3>Results</h3><div>We observed increased expression of liver specific transcripts and production of ApoB containing VLDL in dHuH7.5-NTCP cells and replication of HBV, HDV, HCV and HEV for at least 4 weeks after mono or multiple infections. We recapitulated the known antiviral effect of sofosbuvir on HCV and HEV (&gt;90% reduction in the levels of intracellular viral RNAs, <em>p</em> &lt;0.0005) and of IFN-α on HCV, HEV and HDV (80% reduction in the levels of intracellular viral RNAs, <em>p</em> &lt;0.0005). Besides its already described antiviral effect on HBV and HDV, we observed that GW4064, a farnesoid X receptor (FXR) agonist, also strongly inhibited HEV replication (85 to 95% reduction in the levels of intracellular HEV RNAs, <em>p</em> &lt;0.0005). Using HEV-infected HuHep mice, we confirmed the antiviral effect of vonafexor, an FXR agonist, that is currently being tested clinically against HBV/HDV.</div></div><div><h3>Conclusions</h3><div>We set-up the first <em>in vitro</em> model allowing multi-infections with hepatitis viruses that can be used for broad drug screening and highlighted FXR ligands as potential broad-acting antivirals.</div></div><div><h3>Impact and implications</h3><div>Hepatitis virus infections caused by HBV, HCV, HDV, and HEV represent a global health threat. Treatment options remain limited, notably due to the lack of knowledge about molecular virus-host interactions. Moreover, the interplay between these four viruses in the context of co-infections remains unknown. In this study, we report the first <em>in vitro</em> system that allows for mono and multi-infections with these four viruses and characterize the broad antiviral activity of farnesoid X receptor agonists, paving the way for the development of new strategies for viral cure.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 5","pages":"Article 101383"},"PeriodicalIF":9.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143748546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFNα non-response","authors":"Douglas L. Fink ,&nbsp;David Etoori ,&nbsp;Robert Hill ,&nbsp;Orest Idilli ,&nbsp;Nikita Kartikapallil ,&nbsp;Olivia Payne ,&nbsp;Sarah Griffith ,&nbsp;Hannah F. Bradford ,&nbsp;Claudia Mauri ,&nbsp;Patrick T.F. Kennedy ,&nbsp;Laura E. McCoy ,&nbsp;Mala K. Maini ,&nbsp;Upkar S. Gill","doi":"10.1016/j.jhepr.2025.101382","DOIUrl":"10.1016/j.jhepr.2025.101382","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Type one (T1) and three interferons (T3IFNs) are implicated in chronic hepatitis B (CHB) immunopathogenesis. IFN remains the only licenced immune modulating therapy for CHB. We measured the prevalence of auto-antibodies (auto-Abs) against T1 and T3IFNs to examine the hypothesis that they impact HBV control and treatment response, as highlighted by COVID-19.</div></div><div><h3>Methods</h3><div>Our multi-centre retrospective longitudinal study accessed two CHB cohorts; auto-Ab levels and neutralisation status were measured against T1IFN and T3IFN. Associations were tested against HBV clinical parameters.</div></div><div><h3>Results</h3><div>Overall, 16.7% (46/276) of patients with CHB had any detectable anti-IFN auto-Abs at any time and 6.5% (18/276) anti-T3IFN auto-Abs, with a high incidence of PegIFNα-induced <em>de novo</em> auto-Abs (31.4%, 11/35). However, only a minority of auto-Ab-positive sera demonstrated neutralisation <em>in vitro</em> (4/46, 8.7%). Auto-Ab positivity correlated with higher median HBsAg levels (<em>p</em> = 0.0110). All individuals with detectable anti-T1IFN auto-Abs were PegIFNα non-responders.</div></div><div><h3>Conclusions</h3><div>Non-neutralising anti-IFN auto-Abs are common in CHB and associate with higher median HBsAg levels. Further prospective study of anti-cytokine auto-Abs in CHB are required to characterise the association with long-term outcomes.</div></div><div><h3>Impact and implications</h3><div>HBV and PegIFNα individually may induce broad autoreactivity associated with dysregulated antiviral immune responses. Auto-Ab screening prior to PegIFNα treatment or other immunotherapies may play a critical role in predicting treatment responses.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 5","pages":"Article 101382"},"PeriodicalIF":9.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143815577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}